Article · Wikipedia archive · Last revised Jun 20, 2026

1ZP2MA

1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent of the indolizinylethylamine family. It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring. 1ZP2MA has been found to be a potent dopamine releasing agent, with an EC50 of 62 nM. It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)). 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.

Last revised
Jun 20, 2026
Read time
≈ 1 min
Length
160 w
Citations
5
Source
Wikipedia ↗
1ZP2MA
Clinical data
Other names[1-(Indolizin-1-yl)propan-2-yl](methyl)amine; 1-(Indolizin-1-yl)-N-methylpropan-2-amine; Compound 26-5; Indolizine-NM-AMT; Indolizine-NM-αMT
Drug classMonoamine releasing agent
ATC code
  • None
Identifiers
  • 1-indolizin-1-yl-N-methylpropan-2-amine
PubChem CID
Chemical and physical data
FormulaC12H16N2
Molar mass188.274 g·mol−1
3D model (JSmol)
  • CC(CC1=C2C=CC=CN2C=C1)NC
  • InChI=1S/C12H16N2/c1-10(13-2)9-11-6-8-14-7-4-3-5-12(11)14/h3-8,10,13H,9H2,1-2H3
  • Key:FMOIPWVAARKPNM-UHFFFAOYSA-N

1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent of the indolizinylethylamine family.1 It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring.1 1ZP2MA has been found to be a potent dopamine releasing agent, with an EC50 of 62 nM.1 It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)).1 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.1

See also

See also

References

References

  1. WO patent 2023183613A2, Baggott MJ, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen 
External links